Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
Pleural Mesothelioma
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
Pembrolizumab and Chemotherapy Improve Survival in Patients
Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]
Checkmate743 Showed Higher Toxicity in a Real World Setting
A group of Australian patients receiving Checkmate743 therapy saw higher levels of toxicity compared to CheckMate743 clinical trial patients. Checkmate743 consists of a dual treatment of ipilimumab and nivolumab and is the standard of care for patients with unresectable pleural mesothelioma. Unresectable means patients are not able to receive surgery[…]
A New Biomarker Could Help Doctors Diagnose Mesothelioma
A new biomarker has been found for the diagnosis of mesothelioma by scientists in Japan. Information from this research could revolutionize how mesothelioma is diagnosed and treated in the future. Mesothelioma is a hard cancer to diagnose because it shares symptoms with other cancers. Cancers it can look like include[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
Extended Pleurectomy and Decortication Surgery Worse than Just Receiving Chemotherapy
Extended pleurectomy decortication surgery combined with chemotherapy is associated with worse outcomes compared to just chemotherapy alone. Researchers looked at extended pleurectomy and decortication surgery alongside chemotherapy and found that there are worse survival outcomes, a higher chance of serious adverse events, and a diminished quality of life compared to[…]
PARP Inhibitors Could Soon Help Mesothelioma Patients
There is a new treatment involving PARP inhibitors that could potentially benefit mesothelioma patients. PARP stands for Poly (ADP-ribose) polymerase. PARP is typically involved in repairing damaged DNA in cells. It can be useful against side effects from chemotherapy by repairing damaged tumor cells, which helps tumors to continue growing.[…]
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Primary Outcome Measures Objective Response Rate (ORR) defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. Up to 36 months Secondary Outcome Measures Progression Free Survival (PFS) defined[…]
Galinpepimut-S and Nivolumab are Effective and Safe for Mesothelioma
The combination of galinpepimut-S and nivolumab is showing promising results for mesothelioma. The study looked at patients who were refractory or relapsed after at least one standard treatment. The combination met safety and efficacy standards for treatment, leading to a completed phase one trial. The median overall survival, which was[…]